Literature DB >> 21727941

The placebo effect in overactive bladder syndrome.

Altaf Mangera1, Christopher R Chapple, Zoe S Kopp, Melanie Plested.   

Abstract

Overactive bladder syndrome (OAB) is a condition that involves urinary urgency and affected individuals are usually treated with behavioral therapy and antimuscarinic agents as first-line therapies. Existing evidence from clinical trial data suggests that a positive placebo effect occurs in patients receiving treatment for OAB. In our systematic Review of placebo-controlled, randomized trials in OAB, we show statistically significant improvements in three patient-reported outcomes-incontinence episodes per day, micturition episodes per day and mean micturition volume from baseline-after placebo in randomized studies for OAB. The findings could highlight the brain's role in the pathophysiology of OAB or the role of additional bladder training conducted as part of OAB clinical trials. More research is needed to determine the underlying mechanisms of the placebo effect in OAB.

Entities:  

Mesh:

Year:  2011        PMID: 21727941     DOI: 10.1038/nrurol.2011.99

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN: 1759-4812            Impact factor:   14.432


  62 in total

1.  The powerful placebo.

Authors:  H K BEECHER
Journal:  J Am Med Assoc       Date:  1955-12-24

Review 2.  The effects of antimuscarinic treatments in overactive bladder: a systematic review and meta-analysis.

Authors:  Christopher Chapple; Vik Khullar; Zahava Gabriel; Julie Ann Dooley
Journal:  Eur Urol       Date:  2005-03-22       Impact factor: 20.096

3.  Understanding and harnessing placebo effects: clearing away the underbrush.

Authors:  Franklin G Miller; Howard Brody
Journal:  J Med Philos       Date:  2011-01-10

4.  The treatment of detrusor instability in post-menopausal women with oxybutynin chloride: a double blind placebo controlled study.

Authors:  A J Tapp; L D Cardozo; E Versi; D Cooper
Journal:  Br J Obstet Gynaecol       Date:  1990-06

5.  Randomized, double-blind, multicenter trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity: oxybutynin versus propantheline versus placebo.

Authors:  J W Thüroff; B Bunke; A Ebner; P Faber; P de Geeter; J Hannappel; H Heidler; H Madersbacher; H Melchior; W Schäfer
Journal:  J Urol       Date:  1991-04       Impact factor: 7.450

Review 6.  The role of urinary urgency and its measurement in the overactive bladder symptom syndrome: current concepts and future prospects.

Authors:  Christopher R Chapple; Walter Artibani; Linda D Cardozo; David Castro-Diaz; Michael Craggs; Francois Haab; Vik Khullar; Eboo Versi
Journal:  BJU Int       Date:  2005-02       Impact factor: 5.588

7.  Multicenter phase III trial studying trospium chloride in patients with overactive bladder.

Authors:  Delbert Rudy; Kevin Cline; Richard Harris; Kenneth Goldberg; Roger Dmochowski
Journal:  Urology       Date:  2006-02       Impact factor: 2.649

8.  Brain activity measured by functional magnetic resonance imaging is related to patient reported urgency urinary incontinence severity.

Authors:  Stasa D Tadic; Derek Griffiths; Werner Schaefer; Cathy I Cheng; Neil M Resnick
Journal:  J Urol       Date:  2010-01       Impact factor: 7.450

9.  Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder.

Authors:  P Abrams; R Freeman; C Anderström; A Mattiasson
Journal:  Br J Urol       Date:  1998-06

10.  The therapeutic effect of clinical trials: understanding placebo response rates in clinical trials--a secondary analysis.

Authors:  Harald Walach; Catarina Sadaghiani; Cornelia Dehm; Dick Bierman
Journal:  BMC Med Res Methodol       Date:  2005-08-18       Impact factor: 4.615

View more
  11 in total

Review 1.  Placebo Medication and Sham Surgery Responses in Benign Prostatic Hyperplasia Treatments: Implications for Clinical Trials.

Authors:  Igor Sorokin; Adam Schatz; Charles Welliver
Journal:  Curr Urol Rep       Date:  2015-10       Impact factor: 3.092

2.  CUA guideline on adult overactive bladder.

Authors:  Jacques Corcos; Mikolaj Przydacz; Lysanne Campeau; Gary Gray; Duane Hickling; Christiane Honeine; Sidney B Radomski; Lynn Stothers; Adrian Wagg; Frcp Lond
Journal:  Can Urol Assoc J       Date:  2017-05-09       Impact factor: 1.862

3.  Pharmacologic treatment of pediatric headaches: a meta-analysis.

Authors:  Khalil El-Chammas; Jill Keyes; Nathan Thompson; Jayanthi Vijayakumar; Dorothy Becher; Jeffrey L Jackson
Journal:  JAMA Pediatr       Date:  2013-03-01       Impact factor: 16.193

4.  Efficacy and safety of Baweidihuang-wan in women with overactive bladder: a randomized, double blind, placebo controlled trial.

Authors:  Dongil Kim; Changmin Choi; Insuk Ahn; Ikhan Ryu; Minsun Choi; Younsuk Lee; Myeong Soo Lee
Journal:  Int J Clin Exp Med       Date:  2014-09-15

Review 5.  Management of nocturia in the female.

Authors:  Andrew Chang; Eugene W Lee; Alvaro Lucioni
Journal:  Curr Urol Rep       Date:  2015-03       Impact factor: 3.092

Review 6.  [Chronic pollakiuria: cystectomy or psychotherapy].

Authors:  A Kuffel; K P Kapitza; B Löwe; E Eichelberg; A Gumz
Journal:  Urologe A       Date:  2014-10       Impact factor: 0.639

Review 7.  The placebo and nocebo effects in functional urology.

Authors:  Hadi Mostafaei; Sandra Jilch; Greta Lisa Carlin; Keiichiro Mori; Fahad Quhal; Benjamin Pradere; Ekaterina Laukhtina; Victor M Schuettfort; Abdulmajeed Aydh; Reza Sari Motlagh; Claus G Roehrborn; Shahrokh F Shariat; Sakineh Hajebrahimi
Journal:  Nat Rev Urol       Date:  2021-12-23       Impact factor: 14.432

8.  Overactive bladder, differential diagnosis, and clinical utility of fesoterodine.

Authors:  Jean-Jacques Wyndaele
Journal:  Int J Gen Med       Date:  2012-11-12

Review 9.  Overactive bladder syndrome: Current pathophysiological concepts and therapeutic approaches.

Authors:  Nadir I Osman; Christopher R Chapple
Journal:  Arab J Urol       Date:  2013-09-18

10.  Efficacy and safety of onabotulinumtoxinA in patients with overactive bladder: subgroup analyses by sex and by serum prostate-specific antigen levels in men from a randomized controlled trial.

Authors:  Osamu Yokoyama; Masashi Honda; Tomonori Yamanishi; Yuki Sekiguchi; Kenji Fujii; Kyoko Kinoshita; Takashi Nakayama; Akikazu Ueno; Takao Mogi
Journal:  Int Urol Nephrol       Date:  2021-07-22       Impact factor: 2.370

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.